King for a Day? On What’s Wrong With Changing the World for the Better
By Roland Nadler,
Law and Biosciences Blog
| 01. 04. 2016
Untitled Document
Philosopher Russell Blackford argues that regulatory authorities should not allow “the tyranny of mere public opinion” to impede technological advances in genomics. I disagree strenuously. To explain why, let’s talk for a minute about … Mark Zuckerberg.
It was perhaps the last big Silicon Valley news story of 2015: Facebook’s CEO blew the headlines wide open when he and Dr. Priscilla Chan announced that they will dedicate 99% of their Facebook shares to their eponymous charitable LLC within their lifetimes. Widespread adulation was the order of the day.
You don’t have to be Gawker gadfly Sam Biddle to find some cause for concern, though. Two unelected, unaccountable magnates now wield a $45 billion policymaking LLC, unimpeded by the usual tax-law strictures for charitable organizations. They can and will remake swaths of the world as they see fit. What’s your recourse if you disagree with their definition of “better”? (Think you’ll never disagree? I’ve got some New Jersey charter schools to sell you.)
So, why rehearse the well-worn debate over philanthropy’s democratic legitimacy on a law and biosciences blog? Money isn’t the only way to change the world. Teams...
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...